文献速递间质性肺疾病

VEGF-Axxx异构体差异表达在肺纤维化发展中的关键作用

Differential Expression of VEGF-Axxx Isoforms Is Critical for Development of Pulmonary Fibrosis.
PubMed 文献 · Am J Respir Crit Care Med · 2017-01-01

该研究探讨VEGF-A异构体在特发性肺纤维化(IPF)中的作用,发现IPF患者肺成纤维细胞差异表达并响应VEGF-A165a和VEGF-A165b。进展期IPF患者血浆中VEGF-A165b升高。小鼠模型中,肺泡II型细胞特异性缺失VEGF-A或过表达VEGF-A165b可抑制博来霉素诱导的肺纤维化,提示VEGF-Axxxa与VEGF-Axxxb比值变化在肺纤维化发展中起关键作用。

要点

  • IPF患者肺成纤维细胞差异表达VEGF-A165a和VEGF-A165b。
  • 进展期IPF患者血浆VEGF-A165b升高。
  • 小鼠中抑制VEGF-A或过表达VEGF-A165b可减轻肺纤维化。

核心结论

  • 肺泡II型细胞来源的VEGF-A异构体生物利用度变化,即VEGF-Axxxa与VEGF-Axxxb比值,在肺纤维化发展中起关键作用。

研究设计与样本

  • 使用IPF患者和对照者的组织切片、血浆和肺成纤维细胞。
  • 使用博来霉素诱导肺纤维化模型,野生型MMTV小鼠和条件性诱导肺泡II型细胞特异性VEGF-A缺失的三转基因小鼠。

主要发现

  • IPF和正常肺成纤维细胞在增殖和基质表达方面对VEGF-A165a和VEGF-A165b的差异表达和响应不同。
  • 进展期IPF患者血浆中检测到VEGF-A165b升高。
  • 小鼠模型中,肺泡II型细胞特异性缺失VEGF-A或组成性过表达VEGF-A165b抑制肺纤维化发展。
  • 腹腔注射VEGF-A165b至野生型小鼠同样抑制肺纤维化。

临床怎么用

  • VEGF-Axxxa/VEGF-Axxxb比值可能作为肺纤维化治疗靶点。
  • VEGF-A165b可能具有抑制肺纤维化的治疗潜力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE: Fibrosis after lung injury is related to poor outcome, and idiopathic pulmonary fibrosis (IPF) can be regarded as an exemplar. Vascular endothelial growth factor (VEGF)-A has been implicated in this context, but there are conflicting reports as to whether it is a contributory or protective factor. Differential splicing of the VEGF-A gene produces multiple functional isoforms including VEGF-A165a and VEGF-A165b, a member of the inhibitory family. To date there is no clear information on the role of VEGF-A in IPF. OBJECTIVES: To establish VEGF-A isoform expression and functional effects in IPF. METHODS: We used tissue sections, plasma, and lung fibroblasts from patients with IPF and control subjects. In a bleomycin-induced lung fibrosis model we used wild-type MMTV mice and a triple transgenic mouse SPC-rtTA+/-TetoCre+/-LoxP-VEGF-A+/+ to conditionally induce VEGF-A isoform deletion specifically in the alveolar type II (ATII) cells of adult mice. MEASUREMENTS AND MAIN RESULTS: IPF and normal lung fibroblasts differentially expressed and responded to VEGF-A165a and VEGF-A165b in terms of proliferation and matrix expression. Increased VEGF-A165b was detected in plasma of progressing patients with IPF. In a mouse model of pulmonary fibrosis, ATII-specific deficiency of VEGF-A or constitutive overexpression of VEGF-A165b inhibited the development of pulmonary fibrosis, as did treatment with intraperitoneal delivery of VEGF-A165b to wild-type mice. CONCLUSIONS: These results indicate that changes in the bioavailability of VEGF-A sourced from ATII cells, namely the ratio of VEGF-Axxxa to VEGF-Axxxb, are critical in development of pulmonary fibrosis and may be a paradigm for the regulation of tissue repair.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Barratt SL, Blythe T, Jarrett C, et al. Differential Expression of VEGF-Axxx Isoforms Is Critical for Development of Pulmonary Fibrosis. Am J Respir Crit Care Med. 2017. PMID: 28661183. doi:10.1164/rccm.201603-0568OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。